Ming‐Mo Hou

Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis

Thomas Yau, Chiun Hsu, Tae‐You Kim et al. · Journal of Hepatology · 2019 · 267 citations · Full text

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

B. Sangro, Stephen L. Chan, Robin Kate Kelley et al. · Annals of Oncology · 2024 · 254 citations · Full text

Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.

Thomas Yau, Yoon‐Koo Kang, Tae‐You Kim et al. · Journal of Clinical Oncology · 2019 · 225 citations

Pharmacotherapy, Nivo Monotherapy, Pre-clinical Pharmacology +19

Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation

Siqing Fu, Ming‐Mo Hou, Aung Naing et al. · Annals of Oncology · 2015 · 72 citations · Full text

Mutant P53 Degradation, Mutant P53-mediated Angiogenesis, Angiogenesis +9

Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial

Zhenggang Ren, Michel Ducreux, Ghassan K. Abou‐Alfa et al. · Liver Cancer · 2022 · 71 citations · Full text